Jasper Therapeutics prices $90M public offering of 60M shares at $1.50 per share

Jasper Therapeutics, Inc.

Offering of 60M shares of common stock at $1.50/share; gross proceeds ~$90M before expenses.
Underwriters granted 30-day option to purchase up to 9M additional shares at same price.
Closing expected on or about Jan 27, 2023; proceeds for general corporate purposes.
Directors and executive officers subject to lock-up agreements until April 25, 2023.
Credit Suisse and William Blair act as active book-running managers; Oppenheimer as passive.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Jasper Therapeutics, Inc. entered into Underwriting Agreement with Credit Suisse Securities (USA) LLC, William Blair & Company, L.L.C. and Oppenheimer & Co. Inc. valued at approximately $90 million (effective 2023-01-25).

Action: entry
Agreement: underwriting
Counterparty: Credit Suisse Securities (USA) LLC, William Blair & Company, L.L.C. and Oppenheimer & Co. Inc.
Value: approximately $90 million
Effective: 2023-01-25

Exact text from the filing

On January 25, 2023, Jasper Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Credit Suisse Securities (USA) LLC, William Blair & Company, L.L.C. and Oppenheimer & Co. Inc., as the representatives of the several underwriters named therein (the “Underwriters”), relating to an underwritten public offering (the “Offering”) of 60,000,000 shares of the Company’s voting common stock, $0.0001 par value per share (“Common Stock”).

View on SEC.gov

119 material agreements filed in the last 30 days. Browse all material agreements →

Jasper Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-23-005155

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.